Company AB Science

AB

FR0010557264

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 19:55:00 07/08/2026 +04			5-day change	1st Jan Change
1.000 ^EUR	+24.07%		+84.84%	-34.90%

07-13	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
07-10	AB Science streamlines its portfolio and refocuses on two molecules

Business description: AB Science

AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Number of employees: 31

Sales by Activity: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Pharmaceuticals	1.61M	958K	970K	1.07M	1.17M

See all business segments

Geographical breakdown of sales: AB Science

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Europe	-	-	-	-	955K
outside Europe	-	-	-	-	219K

See all geographic segments

Executive Committee: AB Science

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018
Alexis Bernard PRN	Corporate Officer/Principal	-	-

See AB SCIENCE governance

Composition of the Board of Directors: AB Science

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021
Catherine Johnston-Roussillon BRD	Director/Board Member	68	27/06/2021
Guillemette Latscha BRD	Director/Board Member	-	27/06/2021
Stéphane Ledermann CHM	Chairman	-	07/07/2026

Composition of the Board of Directors

Shareholders: AB Science

Name	Stocks	%	Valuation
UBS Wealth Management SGIIC SA 0.004443 %	3,100	0.004443 %	3 137 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 5.198 %	85,471	5.198 %	32 638 €

Name	Stocks	%	Valuation
Friedland Gestion SAS 4.167 %	64,103	4.167 %	20 081 €

List of AB SCIENCE shareholders

Company details: AB Science

AB Science SA

3, avenue George V

75008, Paris

+33 1 47 20 00 14

http://www.ab-science.com

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+24.07%	+84.84%	-25.15%	-69.88%	92.5M
MERCK & CO., INC.	+0.16%	-1.24%	+59.35%	+20.83%	317B
MERCK KGAA	-1.03%	+0.35%	+32.89%	-11.30%	72.2B
HALOZYME THERAPEUTICS, INC.	+20.24%	+24.93%	+63.94%	+138.10%	11.7B
KYOWA KIRIN CO., LTD.	+1.29%	-0.31%	-4.34%	-5.12%	8.45B
SK BIOPHARMACEUTICALS CO., LTD.	+2.28%	+8.10%	-14.26%	-6.77%	4.75B
BETTA PHARMACEUTICALS CO., LTD.	+14.37%	+22.10%	+4.25%	+55.26%	4.38B
YUHAN CORPORATION	+3.60%	+9.66%	-28.04%	+14.06%	4.26B
SUPERNUS PHARMACEUTICALS, INC.	+1.88%	+6.74%	+15.55%	+44.76%	2.77B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+4.26%	+0.31%	+1.17%	-0.79%	2.26B
Average	+7.11%	+15.86%	+10.54%	+17.91%	42.81B
Weighted average by Cap.	+0.77%	+0.33%	+50.90%	+18.11%